癌症相关血栓形成中的未解问题
本文综述癌症相关静脉血栓栓塞症(VTE)的现有证据,涵盖直接口服抗凝药的有效性、活动性癌症患者抗凝超过6个月的指征及突破性血栓事件的治疗,并提出个体化管理的实用方法;未来需进一步研究抗凝相关出血和VTE复发的因素。
要点
- 直接口服抗凝药在癌症相关VTE中有效。
- 活动性癌症患者抗凝超过6个月有指征。
- 突破性血栓事件患者可有效治疗。
核心结论
- 随机对照试验和观察性研究数据提示直接口服抗凝药在癌症相关VTE中有效,活动性癌症患者抗凝超过6个月有指征,突破性血栓事件患者可有效治疗。
- 未来需进一步研究以更好定义抗凝相关出血和VTE复发的因素,从而辅助临床决策。
研究设计与样本
- 综述,汇总随机对照试验和观察性研究的证据。
主要发现
- 癌症相关VTE患者抗凝相关出血风险升高,且因抗凝药选择及患者和疾病特异性危险因素而异。
- 直接口服抗凝药在癌症相关VTE中有效。
- 活动性癌症患者抗凝超过6个月有指征。
- 发生突破性血栓事件的患者可有效治疗。
关键数值与推荐
- 活动性癌症患者抗凝超过6个月有指征。
临床怎么用
- 作者提出个体化管理的实用方法。
局限性
- 未来需进一步研究以更好定义抗凝相关出血和VTE复发的因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer-associated venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. Treatment of cancer-associated VTE comes with a heightened risk of anticoagulant-related bleeding that differs by choice of anticoagulant as well as by patient- and disease-specific risk factors. Available data from randomized controlled trials and observational studies in cancer-associated VTE suggest that direct oral anticoagulants are effective, continuing anticoagulation beyond six months is indicated in those with active cancer and that patients who develop 'breakthrough' thrombotic events can be effectively treated. We review the evidence that addresses these key clinical questions and offer pragmatic approaches in individualizing care. While significant investigative efforts over the past decade have made impactful advances, future research is needed to better define the factors that contribute to anticoagulant-related bleeding and VTE recurrence, in order to aid clinical decision-making that improves the care of patients with cancer-associated VTE.
引用
- Sanfilippo KM, Moik F, Candeloro M, et al. Unanswered questions in cancer-associated thrombosis. Br J Haematol. 2022. PMID: 35611985. doi:10.1111/bjh.18276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。